Arcutis (NASDAQ: ARQT) officer logs tax RSU sales and major equity grants
Rhea-AI Filing Summary
Arcutis Biotherapeutics insider equity activity mixes sales and new awards. Officer Patrick Burnett sold 6,106 and 181 shares of common stock on March 2, 2026 at weighted average prices of $25.1604 and $25.9140. A footnote explains these sales were made to cover tax withholding obligations from vesting restricted stock units, rather than discretionary open‑market selling.
Burnett also received equity compensation on February 27, 2026, including a stock option grant for 77,000 shares and a 30,000‑share restricted stock unit award, both with no cash exercise or purchase price at grant. Another entry reflects 16,750 RSUs tied to an earlier performance grant whose milestone was certified on August 18, 2022. A separate footnote notes a prior reporting error that understated his beneficial ownership by 18 to 36 shares, now corrected.
Positive
- None.
Negative
- None.
Insights
Activity reflects routine equity compensation grants and tax-withholding sales.
The transactions show Patrick Burnett receiving sizable equity awards from Arcutis Biotherapeutics and selling a smaller number of shares. On February 27, 2026, he was granted a stock option for 77,000 shares and 30,000 restricted stock units with no cash paid at grant.
The Form 4 indicates that 6,106 and 181 shares were sold on March 2, 2026 at weighted average prices of $25.1604 and $25.9140. A footnote states these sales were solely to cover tax withholding from RSU vesting, which is typically more mechanical than discretionary portfolio selling.
Additional footnotes explain vesting schedules for the new option and RSUs, and clarify that a prior reporting error understated beneficial ownership by 18 to 36 shares. These details suggest administrative clean-up and standard compensation practices rather than a directional signal, so the overall impact on the investment case appears neutral.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,106 | $25.1604 | $154K |
| Sale | Common Stock | 181 | $25.914 | $5K |
| Grant/Award | Stock Option (right to buy) | 77,000 | $0.00 | -- |
| Grant/Award | Common Stock | 30,000 | $0.00 | -- |
| Grant/Award | Common Stock | 16,750 | $0.00 | -- |
Footnotes (1)
- On August 8, 2020, the Reporting Person was granted performance-based Restricted Stock Units ("RSUs") subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on August 18, 2022. The remaining RSUs vested in three substantially equal annual installments, such that the RSUs fully vested on August 18, 2025. Reflects holdings following the August 18, 2022 transaction reported herein. Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Due to a scrivener's error on the Reporting Person's Form 4s filed since November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently understated the Reporting Person's ownership by a range of 18 to 36 shares. The corrected number of shares beneficially owned is reflected in this Form 4. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
